title: Ustekinumab is effective and safe in the treatment of Crohn's disease refractory to anti-TNFα in an orthotopic liver transplant patient.
authors.affiliation: Gastroenterology Department Hospital 12 de Octubre, Madrid, Spain pilarmarmon123@telefonica.net.
authors.forename: M
authors.initials: M
authors.lastname: Martínez-Montiel
authors.affiliation: Gastroenterology Department Hospital 12 de Octubre, Madrid, Spain.
authors.forename: Pilar
authors.initials: P
authors.lastname: Piedracoba-Cadahia
authors.affiliation: Gastroenterology Department Hospital 12 de Octubre, Madrid, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Gómez-Gómez
authors.affiliation: Gastroenterology Department Hospital 12 de Octubre, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Gonzalo
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000068582:Certolizumab Pegol / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D000069549:Ustekinumab / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068582:Certolizumab Pegol
keywords: Crohn’s disease; anti-TNFα; orthotopic liver transplant; ustekinumab